Short answer
ARTIVION, INC. (AORT) filed its Q3 2025 10-Q quarterly report on Nov 7, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $113M (up 18.4% year over year) with net income of $7M.
Q3 2025 key financials · XBRL
- Revenue
- $113M
- +18.4% YoY · +0.4% QoQ
- Net income
- $7M
- +384.2% YoY · +383.4% QoQ
- Operating margin
- 11.1%
- Gross margin
- 65.6%
- EPS (diluted)
- $0.14
- +333.3% YoY · +366.7% QoQ
Source: XBRL data from the ARTIVION, INC. (AORT) Q3 2025 10-Q on SEC EDGAR. USD.
ARTIVION, INC. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Capital expenditures $11.5M for nine months ended Sep 30, 2025 vs $9.8M YoY
- Capex focused on manufacturing equipment, software, computer equipment, and leasehold improvements
- No material changes in indemnification obligations or off-balance sheet commitments as of Sep 30, 2025
Risk Factors
- New risk: Italian medical device payback reduced by 75% after judicial challenges, finalized 2025 payment ~€0.1M reflecting regulatory/tax risk update
- Updated regulatory risk: FDA Mtb tissue processing guidance withdrawn May 2025, public comments filed, potential to reduce available safe implantable tissue supply
- Legal/regulatory risk: Increased compliance under Foreign Corrupt Practices Act, UK Bribery Law, Office of Foreign Asset Control, GDPR, and evolving global sustainability and data privacy laws
- Operational risk: Sole-source supplier dependence for BioGlue and On-X products including single suppliers for key components risks supply disruption impacting near-term production
- Financial risk: Foreign currency exposure mainly Euro/USD fluctuations may materially reduce revenues, compounded by inflation and limited ability to pass rising costs to customers
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ARTIVION, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.